Based on ProtTech’s cutting-edge mass spectrometry technique, ProtTech has developed the MHC peptidomics technology platform to De Novo sequence MHC peptide ligands and identify neoantigens without NGS DNA sequencing. This approach is capable of identifying neoantigens from both coding and non-coding regions of the human genome, as well as from the genomes of many human viruses.

ProtTech has developed a novel fusion protein platform, with a series of signaling molecule-P50 fusion proteins that have potential therapeutic use (Patent Pending). All the fusion proteins we have developed have demonstrated exceptionally high expression yields, a rapid development cycle, simple purification processes, and high biological activity. Another important application of our P50 fusion protein platform is in therapeutic Nanobodies (domain antibody). We have demonstrated in our Nanobody-P50 fusion project that a Nanobody-P50 fusion is expressed from an E.coli host at a very high level.